4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 6.2% – Time to Sell?

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) were down 6.2% during mid-day trading on Monday . The stock traded as low as $13.75 and last traded at $13.76. 551,066 shares changed hands during trading, a decline of 34% from the average session volume of 830,914 shares. The stock had previously closed at $14.67.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. The Goldman Sachs Group restated a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.62.

4D Molecular Therapeutics Stock Performance

The business has a 50-day moving average price of $12.21 and a 200-day moving average price of $10.34. The firm has a market capitalization of $760.10 million, a price-to-earnings ratio of -5.23 and a beta of 2.73. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The business had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. As a group, sell-side analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Insider Transactions at 4D Molecular Therapeutics

In other news, insider David Kirn sold 12,415 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the transaction, the insider owned 871,737 shares in the company, valued at $8,760,956.85. This represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 198,574 shares of company stock worth $2,220,985 in the last 90 days. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Persistent Asset Partners Ltd purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $1,936,000. Dimensional Fund Advisors LP lifted its position in 4D Molecular Therapeutics by 77.3% during the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock valued at $4,863,000 after purchasing an additional 227,982 shares during the period. Exome Asset Management LLC acquired a new position in 4D Molecular Therapeutics during the first quarter valued at $1,216,000. Deutsche Bank AG purchased a new stake in 4D Molecular Therapeutics in the second quarter valued at $9,456,000. Finally, Perigon Wealth Management LLC acquired a new stake in 4D Molecular Therapeutics during the 2nd quarter worth about $1,944,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.